New Trump tariffs on pharmaceuticals could double the cost of common prescription drugs, raising prices for medications like ...

Entresto, a combination of an old drug valsartan with a novel neprilysin inhibitor sacubitril from Novartis, which was approved in July for treating heart failure, has been ear-marked by analysts as a ...

If you’re looking at treatment options for heart failure, you may want to learn more about Entresto (sacubitril/valsartan). It’s a prescription drug used to treat ...

Novartis believes its heart failure drug Entresto's clinical data, commercial infrastructure and recognition among cardiologists can help it fend off potential competition from Eli Lilly and ...

Entresto (sacubitril/valsartan) has interactions with alcohol, other medications, and some supplements. For example, Entresto can interact with potassium supplements ...

Entresto is a brand-name prescription medication containing sacubitril and valsartan. The FDA approved generic versions of Entresto in May 2024, and the drug was launched in July 2025. According to ...

A new suit against Novartis comes as the Swiss pharma is trying to fend off several Entresto generic contenders with lawsuits. (Novartis) Novartis is already suing a long list of generics producers ...

In heart failure patients, combination sacubitril/valsartan (Entresto) appeared to be more protective of kidney functioning versus either an angiotensin-converting enzyme (ACE) inhibitor or ...

I've lost about 25 pounds.

Best practice around value-based contracting, which involves tying reimbursement for drugs (or devices or digital health tools, etc.) to proof that they deliver improved outcomes or lower treatment ...

Treatment optimization for heart failure with reduced ejection fraction is the focus of the American College of Cardiology’s 2021 update to its 2017 Expert Consensus Decision Pathway on managing ...

Novartis' drug, which combines sacubitril and valsartan, is the first to directly treat patients with heart failure with preserved ejection fraction. FDA on Tuesday granted Entresto, a combination of ...